Stocktoria
BIOMARIN PHARMACEUTICAL INC BMRN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1999-07-23
BIOMARIN PHARMACEUTICAL INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.2B | $2.9B | $2.4B | $2.1B | $1.8B |
| R&D expense | $921.9M | $747.2M | $746.8M | $649.6M | $628.8M |
| SG&A expense | $1.2B | $1.0B | $892.4M | $823.2M | $759.4M |
| Operating income | $409.5M | $484.2M | $185.8M | $161.0M | -$82.3M |
| Interest expense | — | — | $17.3M | $16.0M | $15.3M |
| Income tax | $133.6M | $114.9M | $20.9M | $8.0M | -$11.3M |
| Net income | $348.9M | $426.9M | $167.6M | $141.6M | -$64.1M |
| EPS (diluted) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 |
| Operating cash flow | $828.0M | $572.8M | $159.3M | $175.9M | $304.5M |
| Free cash flow | $725.0M | $487.4M | $62.6M | $54.9M | $209.0M |
| Cash & equivalents | $1.3B | $942.8M | $755.1M | $724.5M | $587.3M |
| Inventory | $1.3B | $1.2B | $1.1B | $894.1M | $776.7M |
| Total assets | $7.6B | $7.0B | $6.8B | $6.4B | $6.0B |
| Total liabilities | $1.5B | $1.3B | $1.9B | $1.8B | $1.7B |
| Shareholders' equity | $6.1B | $5.7B | $5.0B | $4.6B | $4.3B |
Source: SEC EDGAR filings · CIK 0001048477 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.